Cochlear - Objective mapping of cochlear implants
From 01-01-2013 to 31-12-2016
Description
Many hearing impaired children receive a cochlear implant (CI) between6 and 12 months of age. Prior to switch on, the minimal and maximal stimulation levels for each of the typically 20 electrical stimulation channels have to be mapped to the dynamic range of the individual patient. A CI at a young age is highly advantageous for speech and language development, but it poses great challenges for the technical adjustment of the CI signal processing as this mapping process is based on behavioral responses of the patient. The general aim of this project is the development of an objective methodology for mapping CI parameters based on electrically evoked auditory steady state responses (EASSRs).EASSRs are brain responses recorded with electrodes on the skull following electrical stimulation of the auditory nerve. This project will focus on the development of optimal EASSR stimulation schemes which allow prediction of the CI parameters, as well as on advanced signal processing strategies and algorithmic development for precise and fast detection of the EASSRs. This should lead to an objective and automated mapping procedure which will be evaluated in young children with a CI. This project proposal is highly interdisciplinary and balances on the edge of signal processing(engineering) and audiology (medical sciences). The outcomes of this project will lead to significant advances in each of both domains and will resolve an important medical-technical problem.
Team
- Marc Moonen, Co-promoter
- Jan Wouters, Promoter (External)
- Astrid Van Wieringen, Promoter (External)
Financing
Funding: FWO - Research Foundation - Flanders
Program/Grant Type: FWO Research Grant - FWO Research Grant
Events
2/09/2024:
PhD defense - Martijn Oldenhof
Machine Learning for Advanced Chemical Analysis and Structure Recognition in Drug Discovery
3/09/2024:
Meet the Jury Igor Tetko on Advanced Machine Learning in Drug Discovery
12/09/2024:
Multimodal analysis of cell-free DNA for sensitive cancer detection in low-coverage and low-sample settings
Seminar by Antoine Passemiers
News
STADIUS Alumni Herman Verrelst – new CEO of Biocartis
08 June 2017
Herman Verrelst, the founder of KU Leuven spin-off Cartagenia, who has been working in Silicon Valley, US for the last few years will be returning to Belgium to follow the steps of Rudi Pauwels as CEO of the Belgian diagnostic company, Biocartis.
Supporting healthcare policymaking via machine learning – batteries included!
29 May 2017
STADIUS takes the lead in the data analytics efforts in an ambitious European Project MIDAS.
Marc Claesen gives an interview about his PhD for the magazine of the Faculty of Engineering Sciences "Geniaal"
10 February 2017
Did you know that in Belgium approximately one third of type 2 diabetes patients are unaware of their condition?
Joos Vandewalle is nieuwe voorzitter KVAB
09 October 2016
Op 5 oktober 2016 heeft de Algemene Vergadering van de Academie KVAB Joos Vandewalle verkozen tot voorzitter van de KVAB.